Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

Pfizer Raises Its Guidance and Analysts Up Their Targets - PFE Stock Looks Cheap

Pfizer stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance. It's at just over 8x this year's estimates and 7.8x next year. That's too cheap. Shorting puts works here.

Barchart

Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients

On Tuesday, Merck Co. Inc. (NYSE:MRK) released topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy.

Benzinga

FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply

View Preview

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

RFK Jr has slashed vaccine research. You need to know how perilous that is for the world

The avian flu virus is now just one mutation away from easier transmission among humans. Trump’s health chief is a grave risk to world health, says Prof Devi Sridhar, chair of global public health at the University of Edinburgh

The Guardian - UK

Pfizer Covid vaccine for young children may not be renewed by FDA

Email obtained by Guardian says Pfizer was told approval may not be granted, meaning Moderna may have to fill gap

The Guardian - US

FTSE 100 edges down despite hopes of end to Russia-Ukraine war

Evening Standard

GSK to be paid up to £370 million after patent row settles in US

CureVac – a German pharmaceutical company – settled a long-running patent dispute with rival BioNTech and Pfizer in the US on Thursday.

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

Former Trump official calls Kennedy’s latest move a ‘huge strategic misstep’ that ‘deeply compromises national security’

What Kennedy just canceled will terrify you.

We Got This Covered

HHS phases out mRNA vaccine trials for COVID-19, bird flu - Roll Call

HHS says the elimination of 22 mRNA vaccine development projects for COVID-19 and bird flu signals a shift in vaccine priorities.

Roll Call

Trump Tweets Trigger Stock Swings For Tesla, Boeing, Pfizer—And An Insider Trading Inquiry

When President Donald Trump hits "post" on Truth Social, Wall Street braces for impact.

Benzinga

Pfizer CEO says pharmaceutical companies want to work with Trump to make medicine more affordable

IN FULL

The Independent UK

‘We will work collaboratively’: Big Pharma admits it is discussing Trump’s plan to lower drug prices

Pfizer CEO says drugmakers ‘are all ready to roll up their sleeves and execute’ as president demands more direct-to-consumer options

The Independent UK

Pfizer posts strong earnings despite Trump’s new 'up to 250%' tariff threat

Pfizer beat earnings expectations and improved its outlook for the rest of the year, despite fresh statements from Trump announcing pharma tariffs next week.

Euronews

Pfizer Cost-Cut Initiatives More Than Offset Tariffs Impact, Raises Outlook

On Tuesday, Pfizer Inc. (NYSE:PFE) reported second-quarter 2025 adjusted earnings of 78 cents, compared to 60 cents a year ago, beating the consensus of 57 cents.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Dow Surges Over 100 Points; Pfizer Earnings Top Views

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Tuesday.

Investors Business Daily

Pfizer Smashes Earnings Forecasts And Raises Outlook; Shares Jump

Pfizer stock jumped Tuesday after the S&P 500 pharma titan beat second-quarter expectations on the back of solid cost-cutting measures.

Investors Business Daily

Stock Market Today: Dow Retreats After Back-And-Forth Action; Palantir Makes This Bold Move (Live Coverage)

The major indexes ended the session in negative territory Tuesday.

Barchart

Stock Index Futures Gain on Strong Earnings and Fed Rate-Cut Bets

September S&P 500 E-Mini futures (ESU25) are up +0.24%, and September Nasdaq 100 E-Mini futures (NQU25) are up +0.30% this morning, extending a rebound driven by bets on Federal Reserve interest rate cuts and solid corporate earnings.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Option Volatility And Earnings Report For Aug 4 - 8

It’s another big week on the earnings front this week with some important companies set to report including Palantir, Advanced Micro Devices, Uber Technologies, Pfizer, Disney, Shopify, Arista Networks and McDonald’s.

Benzinga

Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...'

President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences.

Al Jazeera

Tariff wars: Has Donald Trump killed the WTO?

In the wake of Trump’s global trade war, can the World Trade Organization reclaim its role as guardian of free trade?

Euronews

Seven all-American products that are actually 'Made in Europe', set to be hit by US tariffs

Trump’s tariffs are aimed at ostensibly boosting US production and fostering a “local for locals” sensibility. Except, it turns out that several American product staples are actually... "Made in Europe"?

Barchart

Pfizer Stock Is a Value Play Ahead of Earnings - Investors Can Short PFE Puts for Income

Pfizer stock still looks cheap ahead of its upcoming Q2 earnings release on Aug. 5. Moreover, investors can make extra income by selling out-of-the-money (OTM) put options.

Barchart

Pfizer Stock: Analyst Estimates & Ratings

Pfizer has lagged behind the broader market over the past year, but analysts maintain a cautiously optimistic outlook on the stock’s future performance.

The Guardian - UK

Trump’s 15% tariff on medicines will harm patients, say EU drugmakers

Trade group says levy will reduce access, disrupt supply chains and cut R&D

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.